House of Lords backs Lundbeck patent
25 February 2009
James Nurton, London
The UK’s House of Lords has upheld a controversial second-generation patent that had been invalidated at first instance for insufficiency, in a decision that will be welcomed by the pharmaceutical industry
In a unanimous decision, the five Lords (the UK’s highest court) ruled on February 25 that Lundbeck’s patent for escitalopram – branded as Lexapro, Cipralex or Cipramil as well as other names – is valid. The drug is the world’s...
Only subscribers have complete access to Managing IP Magazine,
log in or
subscribe now.
Alternatively take a
free trial, giving you 48-hour access to Managing IP Magazine (some articles and surveys may be excluded).
Subscribe Now
This article is available to subscribers. Please click subscribe to read the rest of the article.
Subscribe
Take a free trial
Please take a free 48-hour trial to gain limited access. Some articles and surveys may be excluded.
Take a free trial